Reaction Biology opens protein production facility

The company has also expanded its available list of methyltransferase and related proteins to 27.

RBC chief technology officer Haiching Ma said, "The new facility expands our space by over 50%, and gives us the ability to greatly expand our production of epigenetic related proteins."

RBC Epigenetics director Konrad Howitz said, "The ability to selectively control gene expression is a holy grail for drug researchers. Drugs that successfully inhibit HMT or DNMT targets could be hugely effective."

RBC now offers 25 HMT/DNMT’s, including all of the human members of the MLL/SET1 family of multi-protein complexes, along with 11 HDAC’s, 4 SIRT’s, 7 HAT’s, and 12 DUB’s, the company said.